Board of Directors
Katherine Brooks is a Vice President at TPG Capital in San Francisco where she focuses primarily on investments in the healthcare sector. Prior to TPG, she worked in investment banking at Goldman, Sachs & Co. focused on healthcare. Katherine received a BS with Honors in Molecular & Cell Biology from Stanford University. She also earned an MBA with Distinction from the Harvard Business School.
Dr Schilling is a Partner and member of the Global Operations team at TPG Capital. At TPG, Dr Schilling has responsibility for leading the Operations efforts for and supporting the investment activity in the Healthcare Portfolio Companies. Dr Schilling also chairs the Board of Nutrition Science Initiative, a not-for-profit focused on nutrition research. Prior to joining TPG, Dr Schilling was a Corporate Officer and Vice President of Sales and Marketing for the US Pharmaceutical business at Abbott Laboratories. While at Abbott, he had Profit and Loss responsibility for multiple franchises, including Primary Care, Endocrinology, Oncology, Renal, Virology, and Mature Products, along with contracting for US Managed Care and Trade. Before joining Abbott, Dr Schilling was a partner at McKinsey and Company, where he served clients across the healthcare landscape—focusing on growth, mergers and acquisitions, commercialization of new products and services, and corporate strategy. Dr Schilling received his Bachelor’s degree with Distinction in Biomedical and Electrical Engineering from Duke University, his Master’s degree in Biomedical Engineering from the Johns Hopkins University, where he was a Bozzelli Scholar, and his MD with Honors from the University of Chicago. Following medical school, Dr Schilling conducted his residency training in General Surgery at the Johns Hopkins Hospital and School of Medicine.
Todd Sisitsky is a Partner of TPG, the global alternative asset management firm. He is the Managing Partner of TPG Capital North America, head of the firm’s global healthcare investing platform, and a member of the firm’s Executive Committee. He has held leadership roles in connection with TPG’s investments in Adare Pharmaceuticals, Aptalis Pharmaceuticals, Biomet, Fenwal Transfusion Therapies, IASIS Healthcare, Surgical Care Affiliates, HealthScope, IMS Health, Immucor, and Par Pharmaceutical. Todd also serves on the board of directors of the global not-for-profit organization, the Campaign for Tobacco-Free Kids, as well as on the Dartmouth Medical School Board of Overseers. Prior to joining TPG in 2003, Todd worked at Forstmann Little & Company and Oak Hill Capital Partners. He received an MBA from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and earned his undergraduate degree from Dartmouth College, where he graduated summa cum laude.